RepliCel Life Sciences EV/EBITDA
Что обозначает EV/EBITDA в RepliCel Life Sciences?
EV/EBITDA RepliCel Life Sciences, Inc. является N/A
Какое определение для EV/EBITDA?
EV / EBITDA - это стоимость предприятия, деленная на прибыль до вычета процентов, налогов, обесценивания и амортизации. При помощи неё измеряется, насколько дорогой является акция, и она более действительна для сравнения компаний, чем для соотношения цены и прибыли. Она измеряет цену (в форме стоимости предприятия), которую инвестор платит в пользу денежного потока компании (в форме EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA компаний в Health Care сектор на TSXV по сравнению с RepliCel Life Sciences
Что делает RepliCel Life Sciences?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Компании с ev/ebitda похож на RepliCel Life Sciences
- Nuheara имеет EV/EBITDA из N/A
- Acerus Pharmaceuticals имеет EV/EBITDA из N/A
- Darelle Online Solutions имеет EV/EBITDA из N/A
- GURU Organic имеет EV/EBITDA из N/A
- Sinofortune имеет EV/EBITDA из N/A
- The Limestone Boat имеет EV/EBITDA из N/A
- RepliCel Life Sciences имеет EV/EBITDA из N/A
- Leviathan Gold имеет EV/EBITDA из N/A
- Intrepid Metals Corp имеет EV/EBITDA из N/A
- Centogene N.V. Eo ,12 имеет EV/EBITDA из N/A
- Comprehensive Healthcare Systems имеет EV/EBITDA из N/A
- Property Connect имеет EV/EBITDA из N/A
- Da Sen имеет EV/EBITDA из N/A